503A vs 503B compounding pharmacies
503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities register with the FDA and can produce larger batches under stricter quality standards. Neither makes an FDA-approved product, but 503B carries more federal oversight.
503A pharmacies
Traditional compounding pharmacies preparing patient-specific prescriptions under state board oversight. They do not require FDA registration as outsourcing facilities.
503B outsourcing facilities
Register with the FDA, follow current good manufacturing practice (cGMP) standards, and can compound larger batches. More federal oversight, but still not producing FDA-approved finished drugs.
Why it matters for patients
A named, verifiable pharmacy — and knowing whether it is 503A or 503B — is a core legitimacy check. Programs that will not name their pharmacy fail this test.
Monitoring and laboratory work
A legitimate programme does not simply ship medication. Before starting a GLP-1, a clinician should establish a baseline — typically weight and BMI, blood pressure, and laboratory work including HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication, and a history of pancreatitis, gallbladder disease, severe gastrointestinal disease or diabetic retinopathy changes the risk calculus and should be discussed.
During treatment, tolerance should be reviewed at each dose escalation rather than automatically. Persistent vomiting, severe abdominal pain radiating to the back, or signs of gallbladder disease warrant prompt clinical contact rather than a message to a chat widget.
Questions to ask your clinician
- Given my history, is a GLP-1 appropriate for me at all — and is there a reason it might not be?
- What baseline laboratory work will you order before I start?
- What is the target dose, and how quickly will we escalate to it?
- What side effects should make me call you rather than wait?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at follow-up, or a different one each time?
Questions to ask about the pharmacy
The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.
What happens when you stop
This is the question the marketing rarely addresses, and it belongs in any honest discussion of cost. In the published extension data, a substantial proportion of lost weight returns after discontinuation — the STEP 1 extension found participants regained roughly two-thirds of the weight they had lost within a year of stopping.
The practical implication is financial as well as clinical. If maintaining the result requires continuing the medication, then the number that matters is not the monthly price but the indefinite monthly price. A programme that is $186 a month is $2,232 a year, and potentially the same again the year after. Anyone comparing providers on a first-month promotion is optimising the wrong variable.
Storage and handling
Compounded GLP-1 preparations are generally refrigerated, and specific storage requirements vary by pharmacy and formulation — this is one reason a provider that will not tell you which pharmacy compounds your medication is withholding something you need. Ask for the beyond-use date, which for a compounded preparation is not the same as a manufacturer's expiry date and is typically much shorter. Never use a preparation that has changed colour, become cloudy, or contains particulates.
Who is actually who: the entities in this transaction
The single biggest source of confusion in telehealth medicine is that people assume one company is doing all of it. Usually four or five separate entities are involved, with different regulators and different duties to you.
| Entity | What it is | Regulated by | What it is NOT |
|---|---|---|---|
| Telehealth company | The website you sign up on. Arranges the consultation, handles billing and logistics. | State corporate practice rules; FTC for advertising | Not a pharmacy. Does not make your medicine. |
| Prescribing clinician | The licensed physician, NP or PA who evaluates you and writes the prescription. | Their state medical or nursing board | Not employed by the pharmacy. Must exercise independent judgement. |
| 503A compounding pharmacy | A state-licensed pharmacy compounding for an individual patient against a specific prescription. | State board of pharmacy; FDA for some provisions | Not FDA-approved. Products are not reviewed before marketing. |
| 503B outsourcing facility | An FDA-registered facility that may compound in bulk without patient-specific prescriptions. | FDA, including cGMP inspection | Still not making FDA-approved products. |
| Manufacturer | Eli Lilly, Novo Nordisk. Makes the FDA-approved branded drug. | FDA — full premarket approval | Not involved in compounded products at all. |
Equally: a provider's statement about which pharmacy it uses is a provider-reported relationship until someone verifies it. We label it that way, and so should you when you read it.
Eligibility, and who is likely to be declined
A licensed clinician decides whether treatment is appropriate. No website can promise you eligibility, and one that implies it should worry you.
Typical criteria for GLP-1 weight management follow the approved labels: a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. Absolute contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, and pregnancy. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or diabetic retinopathy changes the risk calculation and must be disclosed.
Be honest on the intake form. The temptation to shade an answer to secure a prescription is understandable and it is a bad trade: the questions exist because the contraindications are real.
State availability, and why it varies
Availability is not uniform across the United States, and the reasons are structural rather than arbitrary. Clinicians must be licensed in your state, not merely somewhere. Pharmacies must hold a non-resident licence to ship into your state. Some states impose additional telehealth requirements — a synchronous video visit rather than an asynchronous questionnaire, for instance — and some restrict compounded products more tightly than others.
The practical consequence is that a provider genuinely available in Texas may not serve California or North Carolina, and pricing sometimes differs by state as well. Confirm availability for your state before you compare anything else, because a cheaper provider that cannot ship to you is not cheaper.
A decision framework, rather than a winner
A comparison that declares one provider the winner for everybody is not a comparison — it is an advertisement with a table attached. Different patients are optimising for genuinely different things, and the honest structure is to name those things and say which provider serves each.
| If your priority is… | The thing to compare | What usually decides it |
|---|---|---|
| Lowest possible cost, and you are confident you will stay a year | Committed-plan monthly equivalent, and the prepayment required | Whether you can prepay. Found's $169 requires ~$2,028 up front; NexLife's $186 does not |
| Lowest cost with no lock-in | Month-to-month rate only | Ignore every committed-plan headline. Compare the no-commitment numbers to each other |
| Clinical support and someone to call | What the membership actually buys | Mochi's $79 buys unlimited physician and dietitian access. That is a service, not a fee |
| Using your insurance | Prior-authorisation support | PlushCare at $19.99/month. If your plan covers the brand, this beats every cash option |
| An FDA-approved product | Manufacturer-direct pricing | LillyDirect and NovoCare. Foundayo and oral Wegovy are $149 — cheaper than most compounded |
| Not injecting | ODT availability, and its evidence status | ODT costs more and no trial has tested it. Valid only if you genuinely will not inject |
| Predictable cost as your dose rises | Whether price is flat across doses | Flat-rate providers vs escalating ones. The annual gap can exceed $3,000 |
The things a price table cannot show you
Four factors routinely matter more than the fifteen-dollar difference people agonise over, and none of them appear in a pricing column.
Continuity of supply. Compounding of these molecules rests on a legal basis the FDA narrowed sharply in 2025. A provider whose pharmacy is forced to stop leaves you without medication, potentially mid-titration. Ask what the contingency is.
Who you actually see. Some programmes give you a named clinician; others route you to whoever is available, which makes continuity of clinical judgement difficult across dose escalations.
What happens at the top of the ladder. A programme that is cheapest at 2.5mg and most expensive at 15mg is not cheap. Model your cost at the dose you expect to maintain.
Whether they will put it in writing. A provider that answers questions about its pharmacy, its salt form and its cancellation terms by email is telling you something. So is one that will not.
The same question, asked of both
Rather than trusting either provider's marketing, ask both the identical set of questions and compare the answers rather than the advertising. We would ask these seven, in writing:
- What will I pay per month at the highest dose you cover?
- Is there any fee — membership, consultation, laboratory, shipping — that is not in the price you quoted me?
- Which specific pharmacy fills my prescription, and is it a 503A or a 503B facility?
- What is the exact salt form and concentration, and is the vial single-dose or multi-dose?
- If I cancel in month three of a twelve-month plan, what exactly happens to my money?
- If your pharmacy is forced to stop compounding, what happens to my supply?
- Will I see the same clinician at each follow-up?
The provider that answers all seven plainly is demonstrating something that no price table can. In our experience the answers, rather than the prices, are what actually separate these companies.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
Is 503B safer than 503A?
503B facilities follow stricter federal manufacturing standards and more oversight, but neither pathway produces an FDA-approved drug. Both can be legitimate when properly licensed.
Sources
- U.S. Food and Drug Administration — labels and safety communications.
- Peer-reviewed clinical trials cited above.
- Our methodology and medical review policy.
Registration is per-facility, not per-company: one company can operate both. Source: FDCA sections 503A and 503B; FDA compounding guidance.